Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Hematology (Amsterdam, Netherlands)|June 28, 2023
<i>MPL</i> gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in JapanChiho Furuya, Yoshinori Hashimoto, Soji Morishita, et al.
International Journal of Hematology|January 3, 2021
Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosisSoji Morishita, Tomonori Ochiai, Kyohei Misawa, et al.
Hematology (Amsterdam, Netherlands)|January 24, 2022
Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in JapanTerumi Baba, Yoshinori Hashimoto, Hajime Yasuda, et al.
Experimental Hematology & Oncology|January 30, 2016
Identification of AIM2 as a downstream target of JAK2V617FEi Leen Liew, Marito Araki, Yumi Hironaka, et al.
Journal of Thrombosis and Thrombolysis|December 9, 2022
Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemiaChiho Furuya, Yoshinori Hashimoto, Soji Morishita, et al.
Hematology (Amsterdam, Netherlands)|November 15, 2024
A higher <i>JAK2</i>V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia veraChiho Furuya, Yoshinori Hashimoto, Soji Morishita, et al.
International Journal of Hematology|December 20, 2014
Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemiaShuichi Shirane, Marito Araki, Soji Morishita, et al.
Pageof 6